Search Results

You are looking at 21 - 30 of 177 items for :

  • "cetuximab" x
  • All content x
Clear All
Full access

Kristen Keon Ciombor and Tanios Bekaii-Saab

cetuximab and panitumumab (Tables 2 and 3 ); or multiple tyrosine kinases, such as regorafenib, 13 , 14 have also improved the efficacy of mCRC treatment in selected patients, both in combination with cytotoxic chemotherapy and as single agents in some

Full access

Emil Lou, Donna D'Souza, and Andrew C. Nelson

exceptions exist. De Roock et al 2 hypothesized that tumors with the G13D mutation specifically respond better to cetuximab than do other mutations, including other point mutations within the same codon. The authors performed a retrospective study of 7

Full access

Andrew H. Ko and Margaret A. Tempero

. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial . J Clin Oncol 2004 ; 22 : 2610 – 2616 . 44 Kim TE Murren JR

Full access

Aparna Parikh, Chloe Atreya, W. Michael Korn, and Alan P. Venook

. This report describes a patient with KRAS , NRAS , and BRAF wild-type mCRC who experienced disease progression on first-line treatment with FOLFIRI and cetuximab after only 5 months, and subsequently experienced progression on second-line treatment

Full access

Fikri İçli, Hakan Akbulut, Shouki Bazarbashi, Mehmet Ayhan Kuzu, Mohandas K. Mallath, Kakil Ibrahim Rasul, Scott Strong, Aamir Ali Syed, Faruk Zorlu, and Paul F. Engstrom

metastatic colorectal cancer, 47% of those surveyed preferred to use cetuximab in addition to chemotherapy as first-line treatment in patients with wild-type KRAS tumors. Committee members met on March 8, 2009, in Istanbul to discuss the survey results

Full access

Athanassios Argiris

Clin Oncol 1998 ; 17 : A1473 . 58 Bonner JA Giralt J Harari PM . Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or

Full access

Himani Aggarwal, Kristin M. Sheffield, Li Li, David Lenis, Rachael Sorg, and Rebecca Miksad

Background: PTL is a prognostic factor for mCRC. Recent data suggest PTL is also predictive of survival benefit with cetuximab (CET) and bevacizumab (BEV). This study evaluated the prognostic and predictive effect of PTL in patients with KRAS WT

Full access

Paul F. Engstrom

Full access

Benjamin A. Weinberg

chemotherapy, biologic agents are an important component of the arsenal against metastatic CRC (mCRC). Use of cetuximab and panitumumab, which are monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), has evolved substantially over the

Full access

Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck Principal Investigator: Aarti Bhatia, MD, MPH Condition